Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794626 | 0.88 | CA2 (0.41) | DBHHTR2AHTR2CHTR2BPTGS2 | |
| SCHEMBL31063514 | 0.88 | CA2 (0.41) | DBHHTR2AHTR2CHTR2BPTGS2 | |
| SCHEMBL19924948 | 0.86 | KMT2A (0.36) | DBHHTR2AHTR2CHTR2BPTGS2 | |
| SCHEMBL31172071 | 0.79 | SMN1; SMN2 (0.40) | TUBB1CYP3A4MAPTTUBB4ATUBB | |
| SCHEMBL4182654 | 0.79 | SMN1; SMN2 (0.40) | TUBB1CYP3A4MAPTTUBB4ATUBB | |
| SCHEMBL4547651 | 0.79 | PTGS2 (0.58) | DBHHTR2AHTR2CHTR2BPTGS2 | |
| SCHEMBL6600541 | 0.78 | PPARD (0.30) | — | |
| SCHEMBL27161330 | 0.78 | HTR2A (0.38) | HTR2AHTR2CHTR2BPTGS2TUBB1 | |
| SCHEMBL24088153 | 0.77 | DBH (0.44) | DBHHTR2AHTR2CHTR2BPTGS2 | |
| SCHEMBL3764427 | 0.77 | MAPT (0.50) | DBHHTR2AHTR2CHTR2BPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-118164914-A | Indazole compound and synthetic method and application thereof | 华东师范大学 | 2024-06-11 | — | — | CN | disclosed |
| US-20240174613-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | SOUTHERN RES INST (US) | 2024-05-30 | — | — | US | disclosed |
| US-11945781-B2 | Compounds for the treatment of acute and chronic kidney disease | SOUTHERN RESEARCH INSTITUTE (US) | 2024-04-02 | — | — | US | disclosed |
| CN-112218865-B | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4277897-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230339860-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | SOUTHERN RES INST (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339860-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | SOUTHERN RES INST (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-2124970-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008087198-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087198-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| CN-101222928-A | Method for preventing and treating metabolic diseases and novel pyrazole-O-glucoside derivatives | BOEHRINGER INGELHEIM INT (DE) | 2008-07-16 | — | — | CN | disclosed |
| EP-1912656-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | disclosed |
| WO-2007014895-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014895-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | DBH 1129/4885HTR2A 1878/4885HTR2C 1661/4885 |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | IAPP, G6PC1, GPR119 | DBH 693/4885HTR2A 3936/4885HTR2C 3821/4885 |
| US-20230339860-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | HMOX1, HMOX2, GLS | DBH 1125/4885HTR2A 650/4885HTR2C 304/4885 |
| US-20240174613-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | HMOX1, HMOX2, GLS | DBH 1125/4885HTR2A 650/4885HTR2C 304/4885 |
| US-11945781-B2 | Compounds for the treatment of acute and chronic kidney disease | HMOX1, HMOX2, GLS | DBH 1125/4885HTR2A 650/4885HTR2C 304/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | DBH 3805/4885HTR2A 3849/4885HTR2C 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.